Monika A Davare, Anna Saborowski, Christopher A Eide, Cristina Tognon, Rebecca L Smith, Johannes Elferich, Anupriya Agarwal, Jeffrey W Tyner, Ujwal P Shinde, Scott W Lowe, Brian J Druker. Proc Natl Acad Sci U S A 2013
Times Cited: 85
Times Cited: 85
Alexander Drilon, Salvatore Siena, Sai-Hong Ignatius Ou, Manish Patel, Myung Ju Ahn, Jeeyun Lee, Todd M Bauer, Anna F Farago, Jennifer J Wheler, Stephen V Liu, Robert Doebele, Laura Giannetta, Giulio Cerea, Giovanna Marrapese, Michele Schirru, Alessio Amatu, Katia Bencardino, Laura Palmeri, Andrea Sartore-Bianchi, Angelo Vanzulli, Sara Cresta, Silvia Damian, Matteo Duca, Elena Ardini, Gang Li, Jason Christiansen, Karey Kowalski, Ann D Johnson, Rupal Patel, David Luo, Edna Chow-Maneval, Zachary Hornby, Pratik S Multani, Alice T Shaw, Filippo G De Braud. Cancer Discov 2017
Times Cited: 480
Times Cited: 480
List of shared articles
Times cited
ROS1-dependent cancers - biology, diagnostics and therapeutics.
Alexander Drilon, Chelsea Jenkins, Sudarshan Iyer, Adam Schoenfeld, Clare Keddy, Monika A Davare. Nat Rev Clin Oncol 2021
Alexander Drilon, Chelsea Jenkins, Sudarshan Iyer, Adam Schoenfeld, Clare Keddy, Monika A Davare. Nat Rev Clin Oncol 2021
Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer.
Marie-Julie Nokin, Chiara Ambrogio, Ernest Nadal, David Santamaria. Trends Cancer 2021
Marie-Julie Nokin, Chiara Ambrogio, Ernest Nadal, David Santamaria. Trends Cancer 2021
MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer.
Sudarshan R Iyer, Igor Odintsov, Adam J Schoenfeld, Evan Siau, Marissa S Mattar, Elisa de Stanchina, Inna Khodos, Alexander Drilon, Gregory J Riely, Marc Ladanyi,[...]. Mol Cancer Res 2022
Sudarshan R Iyer, Igor Odintsov, Adam J Schoenfeld, Evan Siau, Marissa S Mattar, Elisa de Stanchina, Inna Khodos, Alexander Drilon, Gregory J Riely, Marc Ladanyi,[...]. Mol Cancer Res 2022
Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma.
Lara E Davis, Kevin D Nusser, Joanna Przybyl, Janét Pittsenbarger, Nicolle E Hofmann, Sushama Varma, Sujay Vennam, Maria Debiec-Rychter, Matt van de Rijn, Monika A Davare. Mol Cancer Res 2019
Lara E Davis, Kevin D Nusser, Joanna Przybyl, Janét Pittsenbarger, Nicolle E Hofmann, Sushama Varma, Sujay Vennam, Maria Debiec-Rychter, Matt van de Rijn, Monika A Davare. Mol Cancer Res 2019
Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer.
Annie Roys, Xing Chang, Yang Liu, Xiaobo Xu, Yingliang Wu, Daiying Zuo. Cancer Chemother Pharmacol 2019
Annie Roys, Xing Chang, Yang Liu, Xiaobo Xu, Yingliang Wu, Daiying Zuo. Cancer Chemother Pharmacol 2019
Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies.
Alberto D'Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow, Giandomenico Roviello. Cancers (Basel) 2020
Alberto D'Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow, Giandomenico Roviello. Cancers (Basel) 2020
Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors.
Clare Keddy, Pushkar Shinde, Kristen Jones, Stefanie Kaech, Romel Somwar, Ujwal Shinde, Monika A Davare. Mol Cancer Ther 2022
Clare Keddy, Pushkar Shinde, Kristen Jones, Stefanie Kaech, Romel Somwar, Ujwal Shinde, Monika A Davare. Mol Cancer Ther 2022
Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening.
Gabriele Picco, Elisabeth D Chen, Luz Garcia Alonso, Fiona M Behan, Emanuel Gonçalves, Graham Bignell, Angela Matchan, Beiyuan Fu, Ruby Banerjee, Elizabeth Anderson,[...]. Nat Commun 2019
Gabriele Picco, Elisabeth D Chen, Luz Garcia Alonso, Fiona M Behan, Emanuel Gonçalves, Graham Bignell, Angela Matchan, Beiyuan Fu, Ruby Banerjee, Elizabeth Anderson,[...]. Nat Commun 2019
Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion.
Quincy S Chu. Ther Adv Med Oncol 2020
Quincy S Chu. Ther Adv Med Oncol 2020
ROS1-positive non-small cell lung cancer (NSCLC): biology, diagnostics, therapeutics and resistance.
Zhi-Qiong Yu, Meng Wang, Wen Zhou, Meng-Xia Mao, Yuan-Yuan Chen, Na Li, Xiao-Chun Peng, Jun Cai, Zhi-Qiang Cai. J Drug Target 2022
Zhi-Qiong Yu, Meng Wang, Wen Zhou, Meng-Xia Mao, Yuan-Yuan Chen, Na Li, Xiao-Chun Peng, Jun Cai, Zhi-Qiang Cai. J Drug Target 2022
Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.
Monika A Davare, Jacob J Henderson, Anupriya Agarwal, Jacob P Wagner, Sudarshan R Iyer, Nameeta Shah, Randy Woltjer, Romel Somwar, Stephen W Gilheeney, Ana DeCarvalo,[...]. Clin Cancer Res 2018
Monika A Davare, Jacob J Henderson, Anupriya Agarwal, Jacob P Wagner, Sudarshan R Iyer, Nameeta Shah, Randy Woltjer, Romel Somwar, Stephen W Gilheeney, Ana DeCarvalo,[...]. Clin Cancer Res 2018
Evolution strategy of ROS1 kinase inhibitors for use in cancer therapy.
Siming Liu, Haikui Yang, Ying Jiang, Tingting Zhang, Ruohong Yan, Jiajie Zhang. Future Med Chem 2018
Siming Liu, Haikui Yang, Ying Jiang, Tingting Zhang, Ruohong Yan, Jiajie Zhang. Future Med Chem 2018
Entrectinib: A New Selective Tyrosine Kinase Inhibitor Approved for the Treatment of Pediatric and Adult Patients with NTRK Fusionpositive, Recurrent or Advanced Solid Tumors.
Hind M Osman, Meral Tuncbilek. Curr Med Chem 2022
Hind M Osman, Meral Tuncbilek. Curr Med Chem 2022